Brag House Files First Quarterly Report as Public Company Highlighting Strengthened Balance Sheet, Strategic Partnership with Learfield, and Platform Readiness for Fall Expansion
NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Brag House Holdings, Inc. (NASDAQ: TBH) ('Brag House' or the 'Company'), the Gen Z engagement platform operating at the intersection of gaming, college sports, and digital media, today announced the filing of its Form 10-Q for the quarter ended March 31, 2025. This is the Company's first quarterly report since becoming a publicly listed company in March.
The filing reflects significant balance sheet improvements following the Company's initial public offering, as well as strategic positioning ahead of key growth initiatives scheduled for later this year.
Key Highlights from the Q1 2025 Filing:
Strengthened Capital Position: As of March 31, 2025, the Company held $3.5 million in cash, bolstered by net proceeds from its IPO.
Convertible Debt Eliminated: All $6.6 million of convertible debt including accrued interest was eliminated through equity conversion, significantly strengthening the Company's financial foundation.
Balance Sheet Turnaround: Brag House moved from a $8.5 million deficit to a $1.6 million surplus in stockholders' equity during the quarter, reflecting strong investor confidence as evidenced by the Company's IPO and the full exercise of the Overallotment option.
'This quarter validates the strategy we set in motion leading up to our IPO,' said Lavell Juan Malloy II, CEO and Co-Founder of Brag House. 'We've entered the public markets with a strong balance sheet and a clear plan for scaling revenue, data capabilities, and brand partnerships.'
Strategic Partnership with Learfield Fuels Fall Activation
In Q1, the Company secured a strategic partnership with Learfield Communications, the media and technology powerhouse in college athletics. Through this agreement, Brag House gains access to more than 200 NCAA collegiate properties, including premier football programs and student communities.
Following several successful beta activations, including the inaugural Brag Gators Gauntlet at the University of Florida on May 17, 2025, Brag House is now preparing to launch the Brag Gators series this fall, aligned with the college football season.
This partnership underpins the Company's multi-layered revenue model and supports its evolution into a data-driven platform that delivers anonymized Gen Z behavioral insights to brand partners seeking to lower customer acquisition costs and optimize campaign engagement.
Zacks Valuation Signals Upside Potential
On July 9, 2025, Zacks Small-Cap Research initiated coverage on Brag House with a $4.40 valuation target — more than [6x] the Company's current share price based on the closing price as of July 21, 2025. The report underscores Brag House's differentiated Gen Z-first model and scalable growth potential.
'We are honored to be recognized by Zacks for the strategic and structural foundation we've built,' added Malloy. 'Like Zacks, we believe Brag House is uniquely positioned to scale into a $6.7 billion Total Addressable Market focused on Gen Z.'
About Brag House
Brag House is a leading media technology platform dedicated to transforming casual college gaming into a vibrant, community-driven experience. By merging gaming, social interaction, and collegiate culture, Brag House enables brands to authentically connect with the influential Gen Z demographic through gamified experiences, live-streaming content, and scalable data insights. For more information, visit www.braghouse.com.
Media ContactFatema BhabrawalaDirector of Media Relationsfbhabrawala@allianceadvisors.com
Investor Relations ContactAdele CareyVP, Investor Relationsir@thebraghouse.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
SIMPPLE Ltd. Fully Regains Compliance with Nasdaq's Continued Listing Requirements
Singapore, July 24, 2025 (GLOBE NEWSWIRE) -- SIMPPLE Ltd. (NASDAQ: SPPL) ('SIMPPLE' or 'the Company'), a leading technology provider and innovator in the facilities management (FM) sector, today announced that it has received notice from The Nasdaq Stock Market LLC ('Nasdaq') notifying the Company that the Company has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement and annual shareholder meeting requirement, as required by Nasdaq Listing Rules. As previously reported in the Company's Form 6-K dated January 21, 2025, the Company did not comply with the minimum stockholders' equity of $2,500,000 as required for continued listing on Nasdaq set forth in Nasdaq Listing Rule 5550(b)(1). The Company has since filed a Form 6-K dated July 7, 2025, stating that the Company had executed a series of securities purchase agreements with investors to raise aggregate gross proceeds of $2.0 million resulting from the sale of 1,333,334 shares through a private investment in public equity (PIPE). As a result of the closing of the private placement on June 30, 2025, the Company's shareholders' equity exceeded $2.5 million. SIMPPLE intends to use the net proceeds from the PIPE to advance development of its technologies, extensive pipeline, and global expansion. On July 22, 2025, Nasdaq notified the Company that the Company complies with the Listing Rule 5550(b)(1), subject to the Company's disclosure in a Form 6-K no later than July 25, 2025, providing a description of the completed transaction or event that enabled the Company to satisfy the stockholders' equity requirement for continued listing. Nasdaq will continue to monitor the Company's ongoing compliance with the stockholders' equity requirement and, if at the time of its next periodic report, the Company does not evidence compliance, it may be subject to delisting. At that time, Staff will provide written notification to the Company, which may then appeal Staff's determination to a Hearings Panel. 'We are pleased to have successfully regained compliance with Nasdaq's continued listing requirements and consider this latest notification a key milestone that underscores our broader business objectives' said Norman Schroeder, SIMIPPLE's chief executive. 'We believe it's an important outcome that goes to SIMPPLE's credibility, and best interest of our valued investors, partners, and stakeholders, as we continue to invest in our technology advancements and global growth objectives.' The Company will continue to monitor its ongoing compliance with all applicable Nasdaq listing standards and will provide further updates as and when required. About SIMPPLE LTD. Headquartered in Singapore, SIMPPLE LTD. is an advanced technology solution provider in the emerging PropTech space, focused on helping facilities owners and managers manage facilities autonomously. Founded in 2016, the Company has a strong foothold in the Singapore facilities management market, serving over 60 clients in both the public and private sectors and extending out of Singapore into Australia and the Middle East. The Company has developed its proprietary SIMPPLE Ecosystem, to create an automated workforce management tool for building maintenance, surveillance and cleaning comprised of a mix of software and hardware solutions such as robotics (both cleaning and security) and Internet-of-Things ("IoT") devices. For more information on SIMPPLE, please visit: Safe Harbor Statement This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' or 'hopes' or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. CONTACT: For investor and media queries, please contact: SIMPPLE LTD. Investor Relations Department Email: ir@
Yahoo
an hour ago
- Yahoo
3 Dirt Cheap Stocks to Buy With $1,000 Right Now
Key Points ASML Holdings recently pulled back, but its technology monopoly is intact. Booz Allen Hamilton has been the victim of DOGE cuts but is still a crucial partner for mission-critical defense and intelligence work. Kulicke & Soffa has been forgotten but could be on the brink of recovery. 10 stocks we like better than ASML › The market has soared to new all-time highs in a miraculous recovery from the April 2 "Liberation Day" tariff scare. That being said, the market certainly isn't out of the tariff woods, so to speak, and valuations have now rerated much higher than a mere three months ago. That doesn't leave many "bargains" left in the market. However, the following three stocks have actually lagged the market's recovery because of unique company-specific circumstances. Yet each looks like a bargain at the moment from a longer-term perspective -- especially by today's valuation standards. ASML Holdings Semiconductor equipment giant ASML Holdings (NASDAQ: ASML) might not look "cheap" on the surface, but the stock is actually much cheaper than its recent history. In fact, at around 26 times earnings, the stock is now cheaper than it has been at any time over the past 10 years on a P/E basis except late 2018, just before extreme ultraviolent lithography (EUV) machine sales kicked off in earnest. ASML has traded relatively expensively because it has a monopoly on that critical EUV technology, which is needed to make semiconductor chips with transistors 7nm apart and below. Those types of chips were first produced back in the 2019 time-frame, while the chip industry is currently producing 3nm chips and on its way to 2nm chips later this year or early next year. But while ASML has typically traded at a premium, its valuation has fallen back relatively in line with other semicap equipment names. The most recent downturn in the stock happened this month after Q2 earnings, in which management withdrew guidance for 2026 being a "growth" year, because of tariff-related uncertainty in non-AI markets. While management still projects a strong 15% growth this year, the prospect of a slowdown or decline in 2026 clearly spooked investors, sending the stock down some 15% from recent pre-earnings levels. However, management didn't flag any decline in AI-related tailwinds, nor did it change its longer-term 2030 outlook for revenue between $44 billion and $60 billion, with gross margins between 56% and 60%. That compares with 2025 expectations of $32.2 billion in revenue and gross margins of just 52%. While current tariff and geopolitical controversies may be causing a near-term pause or conservatism on the part of ASML's customers, it shouldn't make much of a difference in the stock's intrinsic value, as long as ASML's competitive advantages and AI-related growth tailwinds remain intact. As of now, those more important factors seem like they're holding strong. Booz Allen Hamilton Consulting firm Booz Allen Hamilton (NYSE: BAH) remains more than 40% off its highs from last fall, on fears over the government's cost-cutting efforts. Booz Allen has become somewhat of an auspicious name in 2025, as the company essentially garners 100% of its business from the U.S. government. As such, investors have fled the stock because the company is the poster child for Department of Government Efficiency (DOGE) cuts. However, Booz Allen is mostly involved in mission-critical, high-tech initiatives for the defense, space, and intelligence services, which encompass 65% of its revenue. That portion of the business is not only high-growth but should also be resistant to too much government austerity. The other 35% of Booz's business is in civil services, and that is where recent DOGE cuts will hurt this year. On its last earnings conference call, Booz Allen management said it anticipates a low double-digit decline in the civil business this year in a one-time "reset." Yet management still forecasts 0% to 4% growth for the whole company for the fiscal year, as the defense/intelligence segment continues to implement next-gen AI solutions into the government's arsenal. And if the civil business stabilizes next year, Booz Allen could see a reacceleration off of this new "base." If that's the case, then Booz Allen's current below-market multiple of just 15 times trailing earnings seems way too cheap. Booz also isn't pulling back from seeking out new tech-forward growth initiatives. The company recently committed $300 million to its Booz Allen Ventures portfolio, which invests in revolutionary defense and cyber-oriented tech startups. That's an increase from the prior $100 million commitment. Management believes it will invest in 20 to 25 new young companies over the next few years. If just one turns out to be a "home run" investment, that could make a big difference in this $14 billion stock, trading at its cheapest valuation in years. Kulicke & Soffa Technology chip packaging leader Kulcike & Soffa (NASDAQ: KLIC) has had a really rough run over the past year or so. After booming in the pandemic period, the company's core ball bonder business has been mired in a post-pandemic funk, as PCs, smartphones, and the auto industry all suffered from severe hangovers. In addition, the company recently had to terminate and write off two significant projects. In 2024, K&S wrote off over $100 million from its advanced display business, after a large customer – supposedly, Apple -- ended its microLED initiative, to which K&S had invested resources. Then in May, K&S announced it would be winding down its money-losing electronics assembly business, resulting in yet another write-off of $87 million. While these wind-downs are unfortunate, neither were in K&S' core chip packaging business, where K&S dominates. On that note, there was actually some positive commentary last quarter. After a long three-year digestion period, K&S management noted utilization of their tools in Taiwan and China -- where most non-auto electronics are assembled -- had reached 80% or more. That's about the rate at which one would expect customers to begin ordering more tools in earnest. But K&S said that customers are holding off because of tariff-related fears. Still, they can only do so for so long if demand holds up. Given that this downcycle has been longer than the typical down-cycle, a strong recovery could be in the making. Additionally, K&S also has a small but growing business in thermocompression bonding (TCB), which can be used in artificial intelligence logic and high-bandwidth memory advanced packaging. That business is expected to reach about $70 million this year, or just over 10% of this year's expected revenue. But management sees this growing fast on the back of AI demand to over $100 million in fiscal 2026, good for about 50% growth. AI-related tailwinds in TCB combined with a recovery in the core ball bonding business could lead to significant upside, given that K&S stock is still a far 53% off its all-time highs. Should you buy stock in ASML right now? Before you buy stock in ASML, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and ASML wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $641,800!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,023,813!* Now, it's worth noting Stock Advisor's total average return is 1,034% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Billy Duberstein and/or his clients have positions in ASML, Apple, Booz Allen Hamilton, and Kulicke And Soffa Industries and has the following options: short December 2025 $55 puts on Booz Allen Hamilton. The Motley Fool has positions in and recommends ASML and Apple. The Motley Fool recommends Booz Allen Hamilton. The Motley Fool has a disclosure policy. 3 Dirt Cheap Stocks to Buy With $1,000 Right Now was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
– Approval is based on the phase 3 CABINET pivotal trial, in which CABOMETYX demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo – – CABOMETYX is the first and only systemic therapy to be approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy – ALAMEDA, Calif., July 24, 2025--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) for the treatment of adult patients with unresectable or metastatic, well-differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This approval follows the positive opinion received from the European Medicines Agency's Committee for Medicinal Products for Human Use in June 2025 and allows for the marketing of CABOMETYX in this indication in all 27 member states of the European Union (EU), Norway, Liechtenstein and Iceland. "The availability of CABOMETYX in the European Union for patients with previously treated advanced neuroendocrine tumors is a significant milestone as there have been limited treatment advancements in the past decade, including very few options shown to improve outcomes across a heterogenous population," said Amy Peterson, M.D., Executive Vice President, Product Development and Medical Affairs, and Chief Medical Officer, Exelixis. "This approval builds on the global CABOMETYX franchise and extends its benefit to even more patients in need of new treatment options. We are proud to partner with Ipsen in our shared commitment to improving the standard of care for people living with advanced, difficult-to-treat cancers." The EC approval is based on results from the phase 3 CABINET pivotal trial, which evaluated CABOMETYX compared with placebo in two cohorts of patients with previously treated NET: advanced pNET and advanced epNET. CABINET was the basis for the U.S. Food and Drug Administration approval of CABOMETYX in March 2025 for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pNET; and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated epNET. About CABINET (Alliance A021602)CABINET (Randomized, Double-Blinded, Phase III Study of CABozantinib versus Placebo In Patients with Advanced NEuroendocrine Tumors After Progression on Prior Therapy) is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and is being led and conducted by the NCI-funded Alliance for Clinical Trials in Oncology with participation from the NCI-funded National Clinical Trials Network, as part of Exelixis' collaboration through a Cooperative Research and Development Agreement with the NCI's Cancer Therapy Evaluation Program. CABINET is a multicenter, randomized, double-blinded, placebo-controlled phase 3 pivotal trial that enrolled a total of 298 patients in two separate cohorts (pNET and epNET) in the U.S. at the time of the final analysis. Patients were randomized 2:1 to cabozantinib (60 mg) or placebo; each cohort was randomized separately and had its own statistical analysis plan. The trial was stopped early after an interim analysis showed superior efficacy associated with cabozantinib as compared to placebo in each of the two cohorts. Patients with epNET had primary tumors arising in the gastrointestinal (GI) tract, lung, unknown primary sites and other organs. Patients must have had measurable disease per RECIST 1.1 criteria and must have experienced disease progression or intolerance after at least one U.S. FDA-approved line of prior systemic therapy other than somatostatin analogs. The primary endpoint in each cohort was PFS per RECIST 1.1 by blinded independent central review. Secondary endpoints included overall survival, objective response rate and safety. More information about this trial is available at About NETNET are cancers that begin in the specialized cells of the body's neuroendocrine system.1 These cells have traits of both hormone-producing endocrine cells and nerve cells.1 It is estimated that 161,000 to 192,000 people in the U.S. are living with unresectable, locally advanced or metastatic NET.2 The number of people diagnosed with NET has been increasing in recent decades.3 Functional NET release peptide hormones that can cause debilitating symptoms, like diarrhea, hypertension and flushing, while symptoms of non-functional NET are related primarily to tumor growth.4,5,6,7,8 Most NET take years to develop and grow slowly, but eventually all patients with advanced or metastatic NET will develop refractory and progressing disease.9,10 NET can start in the pancreas (pNET), where they tend to be more aggressive, with a five-year survival rate of only 23% for advanced disease.1,11 NET can also develop in any part of the body, but most commonly start in the GI tract or in the lungs, where they have historically been referred to as carcinoid tumors and are more recently called epNET.1 The five-year survival rates for advanced GI and lung NET tumors are 68% and 55%, respectively.12,13 For advanced NET patients, treatment options include somatostatin analogs, chemotherapy, molecular targeted therapy and peptide-receptor radionuclide therapy.14 About CABOMETYX® (cabozantinib)In the U.S., CABOMETYX tablets are approved as monotherapy for the treatment of patients with advanced renal cell carcinoma (RCC) and in combination with nivolumab as a first-line treatment for patients with advanced RCC; for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib; for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible; for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pNET; and adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated epNET. CABOMETYX tablets have also received regulatory approvals in over 65 countries outside the U.S. and Japan, including the EU. In 2016, Exelixis granted Ipsen Pharma SAS exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan. In 2017, Exelixis granted exclusive rights to Takeda Pharmaceutical Company Limited for the commercialization and further clinical development of cabozantinib for all future indications in Japan. Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Hemorrhage: CABOMETYX can cause severe and fatal hemorrhages. The incidence of Grade 3-5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies. Discontinue CABOMETYX for Grade 3-4 hemorrhage and before surgery. Do not administer to patients who have a recent history of hemorrhage, including hemoptysis, hematemesis, or melena. Perforations and Fistulas: Fistulas, including fatal cases, and gastrointestinal (GI) perforations, including fatal cases, each occurred in 1% of CABOMETYX patients. Monitor for signs and symptoms, and discontinue CABOMETYX in patients with Grade 4 fistulas or GI perforation. Thrombotic Events: CABOMETYX can cause arterial or venous thromboembolic event. Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients. Fatal thrombotic events have occurred. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic events. Hypertension and Hypertensive Crisis: CABOMETYX can cause hypertension, including hypertensive crisis. Hypertension was reported in 37% (16% Grade 3 and <1% Grade 4) of CABOMETYX patients. In CABINET (n=195), hypertension occurred in 65% (26% Grade 3) of CABOMETYX patients. Do not initiate CABOMETYX in patients with uncontrolled hypertension. Monitor blood pressure regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled; when controlled, resume at a reduced dose. Permanently discontinue CABOMETYX for severe hypertension that cannot be controlled with antihypertensive therapy or for hypertensive crisis. Diarrhea: CABOMETYX can cause diarrhea and it occurred in 62% (10% Grade 3) of treated patients. Monitor and manage patients using antidiarrheals as indicated. Withhold CABOMETYX until improvement to ≤ Grade 1; resume at a reduced dose. Palmar-Plantar Erythrodysesthesia (PPE): CABOMETYX can cause PPE and it occurred in 45% of treated patients (13% Grade 3). Withhold CABOMETYX until PPE resolves or decreases to Grade 1 and resume at a reduced dose for intolerable Grade 2 PPE or Grade 3 PPE. Hepatotoxicity: CABOMETYX in combination with nivolumab in RCC can cause hepatic toxicity with higher frequencies of Grades 3 and 4 ALT and AST elevations compared to CABOMETYX alone. With the combination of CABOMETYX and nivolumab, Grades 3 and 4 increased ALT or AST were seen in 11% of patients. Monitor liver enzymes before initiation of treatment and periodically. Consider more frequent monitoring as compared to when the drugs are administered as single agents. Consider withholding CABOMETYX and/or nivolumab, initiating corticosteroid therapy, and/or permanently discontinuing the combination for severe or life-threatening hepatotoxicity. Adrenal Insufficiency: CABOMETYX in combination with nivolumab can cause primary or secondary adrenal insufficiency. Adrenal insufficiency occurred in 4.7% (15/320) of patients with RCC who received CABOMETYX with nivolumab, including Grade 3 (2.2%), and Grade 2 (1.9%) adverse reactions. Withhold CABOMETYX and/or nivolumab and resume CABOMETYX at a reduced dose depending on severity. Proteinuria: Proteinuria was observed in 8% of CABOMETYX patients. Monitor urine protein regularly during CABOMETYX treatment. For Grade 2 or 3 proteinuria, withhold CABOMETYX until improvement to ≤ Grade 1 proteinuria; resume CABOMETYX at a reduced dose. Discontinue CABOMETYX in patients who develop nephrotic syndrome. Osteonecrosis of the Jaw (ONJ): CABOMETYX can cause ONJ and it occurred in <1% of treated patients. Perform an oral examination prior to CABOMETYX initiation and periodically during treatment. Advise patients regarding good oral hygiene practices. Withhold CABOMETYX for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures. Withhold CABOMETYX for development of ONJ until complete resolution; resume at a reduced dose. Impaired Wound Healing: CABOMETYX can cause impaired wound healing. Withhold CABOMETYX for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of CABOMETYX after resolution of wound healing complications has not been established. Reversible Posterior Leukoencephalopathy Syndrome (RPLS): CABOMETYX can cause RPLS. Perform evaluation for RPLS and diagnose by characteristic finding on MRI any patient presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue CABOMETYX in patients who develop RPLS. Thyroid Dysfunction: CABOMETYX can cause thyroid dysfunction, primarily hypothyroidism, and it occurred in 19% of treated patients (0.4% Grade 3). Assess for signs of thyroid dysfunction prior to the initiation of CABOMETYX and monitor for signs and symptoms during treatment. Hypocalcemia: CABOMETYX can cause hypocalcemia, with the highest incidence in DTC patients. Based on the safety population, hypocalcemia occurred in 13% of CABOMETYX patients (2% Grade 3 and 1% Grade 4). Monitor blood calcium levels and replace calcium as necessary during treatment. Withhold and resume CABOMETYX at a reduced dose upon recovery or permanently discontinue CABOMETYX depending on severity. Embryo-Fetal Toxicity: CABOMETYX can cause fetal harm. Advise pregnant women of the potential risk to a fetus and advise females of reproductive potential to use effective contraception during treatment with CABOMETYX and for 4 months after the last dose. ADVERSE REACTIONS The most common (≥20%) adverse reactions are: CABOMETYX as a single agent: diarrhea, fatigue, PPE, decreased appetite, hypertension, nausea, vomiting, weight decreased, and constipation. CABOMETYX in combination with nivolumab: diarrhea, fatigue, hepatotoxicity, PPE, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection. DRUG INTERACTIONS Strong CYP3A4 Inhibitors: If coadministration with strong CYP3A4 inhibitors cannot be avoided, reduce the CABOMETYX dosage. Avoid grapefruit or grapefruit juice. Strong or Moderate CYP3A4 Inducers: If coadministration with strong or moderate CYP3A4 inducers cannot be avoided, increase the CABOMETYX dosage. Avoid St. John's wort. USE IN SPECIFIC POPULATIONS Lactation: Advise women not to breastfeed during CABOMETYX treatment and for 4 months after the final dose. Hepatic Impairment: In patients with moderate hepatic impairment, reduce the CABOMETYX dosage. Avoid CABOMETYX in patients with severe hepatic impairment. Pediatric Use: Physeal widening has been observed in children with open growth plates when treated with CABOMETYX. Physeal and longitudinal growth monitoring is recommended in children (12 years and older) with open growth plates. Consider interrupting or discontinuing CABOMETYX if abnormalities occur. The safety and effectiveness of CABOMETYX in pediatric patients less than 12 years of age have not been established. Please see accompanying full Prescribing Informationhttps:// You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. About ExelixisExelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of CABOMETYX for patients with previously treated advanced neuroendocrine tumors; Exelixis' or its partner Ipsen's ability or plans to support these new indications for patients in Europe; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: complexities and the unpredictability of the regulatory review and approval processes in the EU and elsewhere; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib; Exelixis' dependence on its relationships with its collaboration partners, including their pursuit of regulatory approvals for partnered compounds in new indications and their adherence to their obligations under relevant collaboration agreements; Exelixis' ability to protect its intellectual property rights; market competition, including the potential for competitors to obtain approval for generic versions of CABOMETYX; changes in economic and business conditions; and other factors affecting Exelixis and its partners to obtain regulatory approval for cabozantinib in new indications; and other factors detailed from time to time under the caption "Risk Factors" in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' other future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. 1 Neuroendocrine Tumors. Cleveland Clinic website. Available at: Accessed July 2025.2 Population Estimate: Unresectable, Locally Advanced or Metastatic Extra-Pancreatic NET. June 2024 (internal data on file).3 Pathak, S., Starr, J.S., Halfdanarson T., et al. Understanding the increasing incidence of neuroendocrine tumors. Expert Rev Endocrinol Metab. September 2023;18(5):377-385.4 Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version. NCI website. Available at: Accessed July 2025.5 What Is a Pancreatic Neuroendocrine Tumor? ACS website. Available at: Accessed July 2025.6 Carcinoid Syndrome. Cleveland Clinic website. Available at: Accessed July 2025.7 Signs and Symptoms of Gastrointestinal Carcinoid Tumors. ACS website. Available at: Accessed July 2025.8 Signs and Symptoms of Lung Carcinoid Tumors. ACS website. Available at: Accessed July 2025.9 McClellan, K., Chen. E.Y., Kardosh A., et al. Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors. Cancers. 2022;14(19):4769.10 What is a Gastrointestinal Carcinoid Tumor? ACS website. Available at: Accessed July 2025.11 Survival Rates for Pancreatic Neuroendocrine Tumor. ACS website. Available at: Accessed July 2025.12 Survival Rates for Gastrointestinal Carcinoid Tumors. ACS website. Available at: Accessed July 2025.13 Survival Rates for Lung Carcinoid Tumors. ACS website. Available at: Accessed July 2025.14 Neuroendocrine Tumor (NET). NCI website. Available at: Accessed July 2025. View source version on Contacts Investors Contact: Susan Hubbard EVP, Public Affairs and Investor Relations Exelixis, Inc. (650) 837-8194 shubbard@ Media Contact: Claire McConnaughey Senior Director, Public Affairs Exelixis, Inc. (650) 837-7052 cmcconn@
